Words of wisdom. Re: anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target

Affiliations

Comment

Philippe Beuzeboc. Eur Urol. 2010 Feb.

. 2010 Feb;57(2):356-7.

doi: 10.1016/j.eururo.2009.11.019.

No abstract available

Comment on

Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target.
Chen Y, Clegg NJ, Scher HI. Chen Y, et al. Lancet Oncol. 2009 Oct;10(10):981-91. doi: 10.1016/S1470-2045(09)70229-3. Lancet Oncol. 2009. PMID: 19796750 Free PMC article.

Endocrine therapy: where do we stand and where are we going?
Schröder FH. Schröder FH. Cancer Surv. 1991;11:177-94. Cancer Surv. 1991. PMID: 1841751 Review.
The G gamma / T-15 transgenic mouse model of androgen-independent prostate cancer: target cells of carcinogenesis and the effect of the vitamin D analogue EB 1089.
Perez-Stable CM, Schwartz GG, Farinas A, Finegold M, Binderup L, Howard GA, Roos BA. Perez-Stable CM, et al. Cancer Epidemiol Biomarkers Prev. 2002 Jun;11(6):555-63. Cancer Epidemiol Biomarkers Prev. 2002. PMID: 12050097
The androgen receptor: a potential target for therapy of prostate cancer.
Santos AF, Huang H, Tindall DJ. Santos AF, et al. Steroids. 2004 Feb;69(2):79-85. doi: 10.1016/j.steroids.2003.10.005. Steroids. 2004. PMID: 15013685 Review.
Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression.
Pizer ES, Pflug BR, Bova GS, Han WF, Udan MS, Nelson JB. Pizer ES, et al. Prostate. 2001 May 1;47(2):102-10. doi: 10.1002/pros.1052. Prostate. 2001. PMID: 11340632
Overview of enzyme inhibitors and anti-androgens in prostatic cancer.
Geller J. Geller J. J Androl. 1991 Nov-Dec;12(6):364-71. J Androl. 1991. PMID: 1769904 Review.